Unichem Labs Appoints P. Bhattacharyya as MD & CEO; Approves FY26 Results
Unichem Laboratories Limited redesignated Pabitrakumar Bhattacharyya as MD & CEO and re-appointed him for three years from August 10, 2026. The company reported consolidated revenue of ₹575.12 crore and profit after tax of ₹10.91 crore for Q4 FY26. Full-year consolidated revenue was ₹2,201.85 crore with a profit after tax of ₹252.84 crore.
Key management changes and the approval of financial results are material events for the company's stakeholders, influencing strategic direction and investor confidence.
The appointment of a CEO and re-appointment of the Managing Director for a long term, along with the approval of financial results, indicates stability and forward-looking management.
Unichem Laboratories Limited announced key management changes and financial results following its Board Meeting held on May 22, 2026. Mr. Pabitrakumar Bhattacharyya has been redesignated from Managing Director to Managing Director & Chief Executive Officer, effective immediately. He has also been re-appointed as MD & CEO for a further period of three years, from August 10, 2026, to August 9, 2029, subject to shareholder approval.
The Board also approved the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended March 31, 2026, and the Audited Financial Statements (Consolidated and Standalone) for the year ended March 31, 2026. The company reported a consolidated revenue from operations of ₹575.12 crore for the quarter ended March 31, 2026, and ₹2,201.85 crore for the full year. Consolidated profit after tax for the quarter was ₹10.91 crore, while for the year it stood at ₹252.84 crore.
In other decisions, the Board re-appointed M/s. Kishore Bhatia & Associates as Cost Auditors and M/s. Ram Agarwal & Associates as Internal Auditors for the financial year 2026-27. The Board meeting commenced at 12:15 p.m. and concluded at 4:00 p.m. The financial statements will be available on the company's website.
What to do with a filing like this
Unichem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other results related. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Unichem Laboratories Limited. Read the original for the full detail.